Adults with type 1 diabetes define what matters to them in stem-cell derived islet cell therapy

Nat Med. 2026 Mar;32(3):797-801. doi: 10.1038/s41591-026-04201-3.

Jane Speight^#^{1

2}, Sufyan Hussain^#^{3

4

5}, Ananthi Anandhakrishnan^{3

4}, Thomas Danne⁶, Esther Latres⁶, Stephen R Karpen⁶, Linxi Mytkolli⁷, Renza Scibilia^{6

8}, Uffe Soeholm^{9

10}, Peter A Senior¹¹; Breakthrough T1D PROMISE Workshop Group

¹ School of Psychology | Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia. jspeight@acbrd.org.au.
² The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria, Carlton, Victoria, Australia. jspeight@acbrd.org.au.
³ Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁴ School of Cardiovascular Medicine and Sciences, King's College London, London, UK.
⁵ Institute of Diabetes, Endocrinology and Obesity, King's Health Partners, London, UK.
⁶ Breakthrough T1D, New York, NY, USA.
⁷ Diabetes Action Canada, Toronto, Ontario, Canada.
⁸ Diabetogenic, Melbourne, Victoria, Australia.
⁹ School of Psychology | Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia.
¹⁰ The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria, Carlton, Victoria, Australia.
¹¹ Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.

^# Contributed equally.

No abstract available